A Phase 1 Clinical Trial Examining the Safety and Pharmacokinetics on Osteoarthritic Knee Pain of ASKC200
- Conditions
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-09-26
- Lead Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06614608
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole
- Conditions
- Interventions
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05631678
- Locations
- 🇨🇳
Drum Tower Hospital of Nanjing University School of Medical, Nanjing, Jiangsu, China
Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT05306132
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Xiangya Hospital Central South University, Changsha, Hunan, China
🇨🇳Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Target Recruit Count
- 214
- Registration Number
- NCT04632108
- Locations
- 🇨🇳
Beijing cancer hospital, Beijing, Beijing, China
🇨🇳Linyi cancer hospital, Linyi, Shandong, China
Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04360915
- Locations
- 🇨🇳
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
- Conditions
- Interventions
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Target Recruit Count
- 337
- Registration Number
- NCT04143607
- Locations
- 🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
🇨🇳Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Beijing Chest Hospital,Capital Medical University, Beijing, Beijing, China
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer
- First Posted Date
- 2018-04-19
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Target Recruit Count
- 507
- Registration Number
- NCT03502850
- Locations
- 🇨🇳
Beijing Chest Hospital,Capital Medical University, Beijing, Beijing, China
🇨🇳Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Tianjin Medical University Cancer Insititute & Hospital, Tianjin, Tianjin, China
Pharmacokinetics and Safety Study of ASKB1202 in Chinese Healthy Subjects
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2017-04-14
- Lead Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Target Recruit Count
- 126
- Registration Number
- NCT03115762